Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Overview of Cell-Matrix Interactions

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First Reported Case of Hemoglobin Graz in the United States: Implications for Misleading Hemoglobin A<sub>1c</sub> Results.

JCEM case reports·2024

Same author

Smartphone-based machine learning model for real-time assessment of medical kidney biopsy.

Journal of pathology informatics·2024

Same author

Prevalence of Phenotypic Hypertrophic Cardiomyopathy Among Student Sports Participants.

The American journal of cardiology·2024

Same author

Metformin toxicity in the intensive care unit: A case series and review of the literature.

International journal of critical illness and injury science·2024

Same author

Fatal hemorrhagic bronchopneumonia caused by <i>Bordetella bronchiseptica</i> in an immunocompetent patient.

Germs·2023

Same author

Extrinsic lipoid pneumonia due to chronic polyethylene glycol consumption: A case report.

Respiratory investigation·2023

Same journal

Understanding basic muscle electrophysiology while keeping an eye on diseases of the heart, lung and blood.

Recent patents on cardiovascular drug discovery·2015

Same journal

Specific antidotes in development for reversal of novel anticoagulants: a review.

Recent patents on cardiovascular drug discovery·2014

Same journal

Pulmonary hypertension in the perioperative period-focus on current and emerging therapies.

Recent patents on cardiovascular drug discovery·2014

Same journal

Beta-blockers in the management of coronary artery disease: are we on the verge of a new paradigm shift?

Recent patents on cardiovascular drug discovery·2014

Same journal

Ticagrelor: a novel drug for an old problem.

Recent patents on cardiovascular drug discovery·2014

Same journal

Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?

Recent patents on cardiovascular drug discovery·2014

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

In Vitro Model of Coronary Angiogenesis

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

Angiogenesis and the heart.

Shree G Sharma¹, Sudip Nanda, Santo Longo

¹Department of Pathology, University of Arkansas, Arkansas, USA. drshreegopal@gmail.com

Recent Patents on Cardiovascular Drug Discovery

|September 30, 2010

Summary

This summary is machine-generated.

Cardiovascular disease is rising globally. This review explores new angiogenesis treatments and patents for cardiac patients lacking other options.

More Related Videos

The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

Published on: November 2, 2016

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Experiment Videos

Last Updated: Jun 8, 2026

In Vitro Model of Coronary Angiogenesis

In Vitro Model of Coronary Angiogenesis

Published on: March 10, 2020

The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

The Arteriovenous (AV) Loop in a Small Animal Model to Study Angiogenesis and Vascularized Tissue Engineering

Published on: November 2, 2016

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Area of Science:

Cardiovascular Medicine
Regenerative Medicine
Biotechnology

Background:

Global incidence of cardiovascular disease is increasing.
Many cardiac patients are unsuitable for current treatments, creating a 'no-option' subgroup.
This subgroup drives innovation in cardiac angiogenesis therapies.

Purpose of the Study:

To review current treatment modalities for cardiac angiogenesis in 'no-option' patients.
To discuss patents filed to advance cardiac angiogenesis.
To highlight the importance of developing new therapies for this patient population.

Main Methods:

Literature review of treatment modalities for cardiac angiogenesis.
Analysis of filed patents related to cardiac angiogenesis.
Synthesis of information on therapeutic approaches and intellectual property.

Main Results:

Several treatment modalities are being explored for cardiac angiogenesis.
Numerous patents have been filed, indicating significant research and development activity.
The field of cardiac angiogenesis is rapidly evolving in response to unmet clinical needs.

Conclusions:

Angiogenesis offers a promising therapeutic avenue for 'no-option' cardiovascular patients.
Ongoing research and patent filings underscore the potential of this field.
Further development is crucial to translate these advancements into clinical practice.